Researchers developed RNACOREX, a new open-source software tool that identifies gene regulation networks in cancer. The tool analyzes thousands of molecules simultaneously to detect key interactions, providing an interpretable molecular map that improves understanding of tumors.
A large Spanish multicenter clinical trial found that a calorie-reduced Mediterranean diet combined with moderate exercise reduces type 2 diabetes risk by 31%. The intervention group also lost weight and reduced waist circumference, preventing approximately three in every 100 participants from developing the disease.
Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.
Researchers at the University of Navarra present a new prediction methodology to improve fairness and reliability of AI models used in critical decision-making. The methodology optimizes parameters of reliable machine learning models, reducing inequalities related to sensitive attributes.
Researchers at the University of Navarra have developed an AI model, known as the IFIT score, to personalize immune therapies for oncology patients. The system analyzes data from over 3,000 patients and identifies novel genetic signatures to improve immunotherapy treatment effectiveness.
Researchers from Cima University of Navarra have found that inhaling menthol improves cognitive ability in animal models of Alzheimer's disease by modulating the immune system and reducing interleukin-1-beta levels. This study opens doors to developing therapies based on stimulating and training the olfactory system.
Researchers have generated artificial mice that mimic the genetic and immunological diversity of multiple myeloma in patients, allowing for more effective and personalized treatments. The mouse avatars can also predict treatment outcomes and identify correlations between genetic traits and response to preclinical therapies.
Researchers at Universidad de Navarra identified a biomarker that predicts CAR T cell therapeutic capacity, which could improve treatment outcomes for patients. The study found that high CAR density in CAR T cells is associated with a worse clinical response in hematological tumors.
A study by Cima and Clinica Universidad de Navarra has identified reparative cardiac fibroblasts that play a crucial role in repairing the heart after an infarction. These cells are activated when a patient suffers a heart attack, producing a collagen scar to prevent rupture of the ventricular wall.
Cima Universidad de Navarra researchers have developed a novel method for detecting COVID-19, achieving over 95% sensitivity in asymptomatic cases. The platform uses a ribonucleic acid (RNA) extraction method that allows for large-scale processing of samples, enabling efficient testing of populations.
A new treatment using niraparib after conventional chemotherapy improves progression-free survival and reduces risk of relapse or death in patients with advanced ovarian cancer. The study, led by Dr. Antonio González Martín, found a significant reduction in risk of relapse, especially in patients with homologous recombination deficiency.
Researchers at the University of Navarra found that pretreating patients with TNF inhibitors before combining immunotherapy can reduce adverse effects and improve treatment response in animal models. The study suggests a new approach to treating cancer by blocking tumor necrosis factor while applying combination immunotherapy.
Researchers at Cima, Clínica Universidad de Navarra have identified three biomarkers associated with atrial fibrillation risk, including CITP, MMP-1, and PICP. These biomarkers can help optimize treatment and follow-up for patients with this cardiac ailment.
A team of researchers at CIMA University has identified a new gene, FOSL1, which is critical in the development of lung and pancreatic cancers. Inhibiting this gene has been shown to drastically reduce tumor size in various experimental models.
A recent international multicenter study has identified a molecule that can help personalize treatment for heart failure. Researchers have found that an excess of lysyl oxidase-like 2 produces fibrosis of the cardiac muscle, impeding its normal functioning and stimulating HF development. The elimination of this excess repairs fibrosis ...